Episode Details
Back to Episodes284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
Published 2 years, 10 months ago
Description
We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoning area in oncology. We’ll also talk about the latest news in the life sciences, including safety concerns for CAR-T cancer treatment, the slumping industry job market, and some curious explanations for clinical failures.